Testosterone in chronic heart failure

Frontiers of Hormone Research

Volumn 37, Issue , 2009, Pages 183-196

  Malkin, Chris J ^a   Jones, T Hugh ^b,d   Channer, Kevin S ^a,c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^d BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANABOLIC AGENT; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; IMMUNOGLOBULIN; LOOP DIURETIC AGENT; METHANEARSONATE DISODIUM; NANDROLONE DECANOATE; PENTOXIFYLLINE; SPIRONOLACTONE; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANGINA PECTORIS; AXIS; BODY COMPOSITION; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CATABOLISM; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG METABOLISM; ENDURANCE; FLUID RETENTION; FUNCTIONAL STATUS; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HEMODYNAMICS; HISTORY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MORBIDITY; PATHOPHYSIOLOGY; POPULATION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SIDE EFFECT; SYNDROME; TESTOSTERONE BLOOD LEVEL; DRUG EFFECT; MALE; PHYSIOLOGY;

BODY COMPOSITION; CHRONIC DISEASE; HEART FAILURE; HEMODYNAMICS; HUMANS; INSULIN RESISTANCE; MALE; PHYSICAL ENDURANCE; TESTOSTERONE;

EID: 59849123908     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000176053     Document Type: Review

References (27)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
2. Anker SD, Coats AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-130.
3. Anker SD, Chua T P, Ponikowski P, Harrington D, Swan J W, Kox WJ, et al: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-534.
4. Jankowska EA, Biel B, Majda J, Szklarska A, Lopus -zanska M, Medras M, et al: Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114: 1829-1837.
5. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, et al: Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-183.
6. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS: Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27:57-64.
7. Coats AJ: Heart failure: what causes the symptoms of heart failure? Heart 2001;86:574-578.
8. Wu FC, von Eckardstein A: Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
9. Malkin CJ, Pugh PJ, Jones TH, Channer KS: Testosterone for secondary prevention in men with ischaemic heart disease? QJM 2003;96:521-529.
10. Scheuer J, Malhotra A, Schaible TF, Capasso J: Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987;61:12-19.
11. Urhausen A, Albers T, Kindermann W: Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004;90:496-501.
12. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al: Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-293.
13. Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Bjornholm M, Heinonen OJ, et al: Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003;550:305-315.
14. Kapoor D, Goodwin E, Channer KS, Jones TH: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154: 899-906.
15. Malkin CJ, Jones TH, Channer KS: The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007;9:44-50.
16. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocri nol Metab 2004;89:3313-3318.
17. Pugh PJ, Jones RD, Malkin CJ, Hall J, Nettleship JE, Kerry KE, et al: Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res 2005;31:271-283.
18. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS: Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-447.
19. Jones RD, Pugh PJ, Jones TH, Channer KS: The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-744.
20. Scragg JL, Jones RD, Channer KS, Jones TH, Peers C: Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun 2004;318:503-506.
21. 2+ channels in A7r5 cells by physiological levels of testosterone. Endocri nology 2006;147:2675-2680.
22. Malkin CJ, Jones RD, Jones TH, Channer KS: Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 2006;111:265-274.
23. Pugh PJ, Jones TH, Channer KS: Acute haemody-namic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-915.
24. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-1696.
25. English KM, Steeds R P, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102: 1906-1911.
26. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al: Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90: 871-876.
27. Tomoda H: Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idio-pathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999;83:123-125, A9.